Overview

Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)

Status:
Terminated
Trial end date:
2021-01-30
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied three times daily will suppress Squamous Cell Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Kavita Sarin
Collaborator:
Medivir
Treatments:
Benzoic Acid